Details

Autor(en) / Beteiligte

• Ashenhurst, James R.
• Nhan, Hoang
• Shelton, Janie F.
• Wu, Shirley
• Tung, Joyce Y.
• Elson, Sarah L.
• Stoller, James K.
• Agee, Michelle
• Aslibekyan, Stella
• Auton, Adam
• Babalola, Elizabeth
• Bell, Robert K.
• Bielenberg, Jessica
• Bryc, Katarzyna
• Bullis, Emily
• Cameron, Briana
• Coker, Daniella
• Partida, Gabriel Cuellar
• Dhamija, Devika
• Das, Sayantan
• Filshtein, Teresa
• Fletez-Brant, Kipper
• Fontanillas, Pierre
• Freyman, Will
• Gandhi, Pooja M.
• Heilbron, Karl
• Hicks, Barry
• Hinds, David A.
• Huber, Karen E.
• Jewett, Ethan M.
• Jiang, Yunxuan
• Kleinman, Aaron
• Kukar, Katelyn
• Lane, Vanessa A.
• Lin, Keng-Han
• Lowe, Maya
• Luff, Marie K.
• McCreight, Jennifer C.
• McIntyre, Matthew H.
• McManus, Kimberly F.
• Micheletti, Steven J.
• Moreno, Meghan E.
• Mountain, Joanna L.
• Mozaffari, Sahar V.
• Nandakumar, Priyanka
• Noblin, Elizabeth S.
• O’Connell, Jared
• Petrakovitz, Aaron A.
• Poznik, G. David
• Schumacher, Morgan
• Shastri, Anjali J.
• Shi, Jingchunzi
• Shringarpure, Suyash
• Tian, Chao
• Tran, Vinh
• Wang, Xin
• Wang, Wei
• Weldon, Catherine H.
• Wilton, Peter

Titel

Prevalence of Alpha-1 Antitrypsin Deficiency, Self-Reported Behavior Change, and Health Care Engagement Among Direct-to-Consumer Recipients of a Personalized Genetic Risk Report

Ist Teil von

• Chest, 2022-02, Vol.161 (2), p.373-381

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Alpha-1 antitrypsin deficiency (AATD) is an autosomal co-dominant condition that predisposes to emphysema, cirrhosis, panniculitis, and vasculitis. Underrecognition has prompted efforts to enhance early detection and testing of at-risk individuals. Direct-to-consumer (DTC) genetic testing represents an additional method of detection. The study addressed three questions: (1) Does a DTC testing service identify previously undetected individuals with AATD? (2) What was the interval between initial AATD-related symptoms and initial diagnosis of AATD in such individuals? and (3) What was the behavioral impact of learning about a new diagnosis of AATD through a DTC test? In this cross-sectional study, 195,014 individuals responded to a survey within the 23andMe, Inc. research platform. Among 195,014 study participants, the allele frequency for the PI∗S and PI∗Z AATD variants was 21.6% (6.5% for PI∗Z and 15.1% for PI∗S); 0.63% were PI∗ZZ, half of whom reported having a physician confirm the diagnosis. Approximately 27% of those with physician-diagnosed AATD reported first becoming aware of AATD through the DTC test. Among those newly aware participants, the diagnostic delay interval was 22.3 years. Participants frequently shared their DTC test results with health care providers (HCPs) and the reported impact of learning a diagnosis of AATD was high. For example, 51.1% of PI∗ZZ individuals shared their DTC result with an HCP. The OR for PI∗ZZ smokers to report smoking reduction as a result of receiving the DTC result was 1.7 (95% CI = 1.4-2.2) compared with those without a Z allele and for reduced alcohol consumption this was 4.0 (95% CI = 2.6-5.9). In this largest available report on DTC testing for AATD, this test, in combination with clinical follow-up, can help to identify previously undiagnosed AATD patients. Moreover, receipt of the DTC AATD report was associated with positive behavior change, especially among those with risk variants. [Display omitted]